Anthem Biosciences IPO GMP & Review: Apply or Avoid?

Anthem Biosciences IPO is open for bidding on 14th July 2025. It is a book-building IPO of 5.96 crore shares worth ₹3,395.00 crores. It is entirely a fresh issue. The issue will be listed on BSE and NSE on its tentative listing date, 21st July 2025. 

Anthem Biosciences IPO Details

The Anthem Biosciences IPO date is fixed between 14th July 2025 and 16th July 2025. The face value of Anthem Biosciences Limited shares stands at ₹10 per share, and the IPO price band is fixed at ₹540 to ₹570 per share. 

Kfin Technologies Limited is the registrar of the Anthem Biosciences IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below. 

Anthem Biosciences IPO Share Reservation

Anthem Biosciences IPO is a bookbuilding IPO issue of 5.96 crore shares worth ₹3,395.00 crores. Anthem Biosciences Limited shares will be listed on the BSE and NSE. Furthermore, SEBI has specified the share reservation criteria for different investor categories. 

Click here to download Smartworks Coworking Spaces RHP for detailed information.

Anthem Biosciences IPO GMP Grey Market Premium

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Do you want to get live updates on the Anthem Biosciences IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

As of 11th July 2025, Anthem Biosciences IPO GMP stands at ₹29 per share, which means the share will likely show a listing at ₹436 (407+29) on its tentative listing date, 21st July 2025.

GMP data is subject to change based on market trends and sentiments. You should check the live GMP status before applying for the Anthem Biosciences IPO. 

Stay updated on Univest to know about live IPOs and their GMP trends! 

Anthem Biosciences IPO Review

Check out the detailed Anthem Biosciences IPO review for a thorough understanding of its potential to report listing gains on 21st July 2025. The Anthem Biosciences IPO review below will help you invest effectively to avoid significant losses. Explore more to make informed investment decisions on this IPO. 

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Thus, it is essential to understand the growth margins and declines of the business’s financials before applying for the Anthem Biosciences IPO.

Anthem Biosciences Limited’s revenue rose 30.15% from ₹1,483.07 crores in March 2024 to ₹1,930.29 crores in March 2025. Moreover, the company’s PAT increased by 22.85% from ₹367.31 crores to ₹451.26 crores. 

Anthem Biosciences Limited has shown consistent revenue growth, indicating that the company is financially stable. Moreover, the brokers, investors, and RAs have a positive outlook for the Anthem Biosciences IPO for its tentative listing day, which is 21st July 2025.  

Technical Analysis

A number of technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technicals of the Anthem Biosciences IPO.

The PE ratio of Anthem Biosciences Limited shares is 70.62, and its Earnings Per Share (EPS) stands at 8.07. Thus, the Anthem Biosciences IPO can potentially deliver gains on its tentative listing date, 21st July 2025. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Anthem Biosciences Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

Anthem Biosciences Limited Peer Comparison

Anthem Biosciences IPO Subscription Status

Anthem Biosciences IPO is to be opened for bidding on 14th July 2025. The subscription status for this IPO is yet to be announced. Stay informed on this passage to check the live Anthem Biosciences IPO Subscription Status. 

About Anthem Biosciences Limited

Anthem Biosciences Limited was incorporated in 2006 and is an innovation-driven, technology-focused contract research organisation with fully integrated operations. The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale. As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesised molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialised molecules). Here are the major competitive strengths of Anthem Biosciences Limited.

• One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India’s fastest growing CRDMO.
• Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
• Specialised business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
• Long-standing relationships with a large, diversified and loyal customer base.
• Professional and experienced leadership team supported by a qualified scientific talent pool.

Anthem Biosciences Limited Financials

The company’s financial analysis is essential before applying for the Anthem Biosciences IPO. Look at the table to learn about Anthem Biosciences Limited’s financials. 

Explanation

Anthem Biosciences Limited’s revenue rose 30.15% from ₹1,483.07 crores in March 2024 to ₹1,930.29 crores in March 2025. Moreover, the company’s PAT increased by 22.85% from ₹367.31 crores to ₹451.26 crores. 

Anthem Biosciences IPO Bidding Requirements

Anthem Biosciences IPO has reserved lot sizes to be applied by different investor categories. Look at the table below to know about the requirements to be fulfilled for applying for this IPO. 

Use the lot size calculator to find how many shares you should apply!

Anthem Biosciences IPO Promoter Holdings

Have a look at the table below to check the holdings of Anthem Biosciences Limited’s promoters: Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj. 

Note: Promoter Holdings’ value is to be calculated using Equity dilution, which represents the gap between shareholdings before and after the Issue. 

Aim of Anthem Biosciences IPO

Anthem Biosciences Limited will not receive any proceeds from this offer for sale and all the proceeds will be received by the selling shareholders. 

Should I Invest in Anthem Biosciences IPO?

“ABL is one of the leading global players in innovation driven, technology focused CRDMO segment. It enjoys niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods. Higher net for FY23 is attributed to exceptional income adjustment for the said year. Though prima-facie the issue appears aggressively priced, investors may park funds for long term.”~Dilip Davda (Chief Editor at Chittorgarh)

Explore the pros and cons of Anthem Biosciences IPO to know whether you should apply or avoid the issue. These pros and cons might help you know about the IPO’s efficiency in delivering profits in the coming decades. 

Pros of Anthem Biosciences IPO

• Innovation Focused Approach
• Long-Standing Customer Relationship 

Cons of Anthem Biosciences IPO

No Consequences

How to Apply for Anthem Biosciences IPO?

Check the steps mentioned below to apply for the Anthem Biosciences IPO. 

• Step 1: Conduct thorough research on Anthem Biosciences IPO GMP, subscription status, issue size, lot size, and other details. 
• Step 2: Open a demat account on Univest to learn about real-time insights on GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
• Step 3: Make a bid for 1 lot of 26 shares worth ₹14,820 of Anthem Biosciences IPO.   
• Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Anthem Biosciences IPO from more than one demat account to increase your allotment chances. 

Also Read : Valencia India IPO GMP & Review: Apply or Avoid?

How to Check Anthem Biosciences IPO Allotment Status?

You can check for Anthem Biosciences IPO allotment in different ways. These include NSE and the registrar portal. Look at the steps mentioned below to check your allotment status online.

Check On NSE

• Visit the NSE Official Website.
• Navigate to the IPO Allotment Section. 
• Select Equity as the issue type. 
• Choose Anthem Biosciences IPO.  
• Choose whether to proceed with the PAN number or the application number.
• Submit your details to get the allotment status online. 

Check On the Registrar Portal

• Visit the registrar portal. 
• Click on the allotment option.
• Fill in the required details.
• Click on the submit button to know your Anthem Biosciences IPO allotment status.

Let’s Wrap

Anthem Biosciences IPO is a book-building issue of 5.96 crore shares worth ₹3,395.00 crores. The shares of Anthem Biosciences Limited will be listed on NSE and BSE on its tentative listing date of 21st July 2025. Researching the Anthem Biosciences IPO GMP and reviews is highly suggested to book your ideal profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Open a demat account on Univest now to initiate your investment journey!

FAQs on Anthem Biosciences IPO

How is the Anthem Biosciences IPO?

Ans. Currently, on 11th July 2025, Anthem Biosciences IPO GMP (Grey Market Premium) stands at ₹29 (7.12% up). It indicates that the estimated listing price could be ₹436 per share. It is a book building IPO of 5.96 crore shares worth ₹3,395.00 crores. The face value of each share of Anthem Biosciences Limited is ₹2. 

What is the Anthem Biosciences IPO price?

Ans. Anthem Biosciences IPO price band has been set between ₹540 and ₹570 per share. Retail investors can apply for a minimum of 1 lot consisting of 26 shares worth ₹14,820. Moreover, HNIs are required to bid for a minimum of 13 lots (338 shares) worth ₹1,92,660. 

Is the Anthem Biosciences IPO good?

Ans. Anthem Biosciences Limited’s revenue rose 30.15% from ₹1,483.07 crores in March 2024 to ₹1,930.29 crores in March 2025. Moreover, the company’s PAT increased by 22.85% from ₹367.31 crores to ₹451.26 crores. Investors can analyse other relevant factors and make a decision accordingly.

Who is the registrar of the Anthem Biosciences IPO?

Ans. Kfin Technologies Limited is the registrar of the Anthem Biosciences IPO, awaiting to manage the IPO allotment procedure and refund initiation. For any queries regarding the Anthem Biosciences IPO allotment and refund, you can contact Kfin Technologies Limited at reachus@kfintech.com or 04067162222.

What is the issue size of the Anthem Biosciences IPO? 

Ans. Anthem Biosciences IPO is a book-building IPO for 5.96 crore shares worth ₹3,395.00 crore. Moreover, the IPO is set to open on 14th July 2025 and will close on 16th July 2025. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Anthem Biosciences IPO, download the Anthem Biosciences IPO RHP and Anthem Biosciences IPO DRHP. Conduct your own research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Upcoming IPOs

Current & Previous IPOs

Read Our Articles on the Best Stocks

Tech Stocks in India to Invest in 2025 | Tech Sector Stocks 

Best Battery Stocks in India to Invest in 2025 | Battery Sector Stocks 

Best Shipping Stocks in India to Invest in 2025 | Shipping Sector Stocks 

Paint Stocks in India to Invest in 2025 | Paint Sector Stocks 

Paper Stocks in India to Invest in 2025 | Paper Sector Stocks 

Best Semiconductor Stocks in India 2025 

Best Large Cap Stocks in India 2025 

Green Energy Penny Stocks

Best Cement Stocks To Invest in India

Also Explore

Univest Screeners

Explore Webstories on Univest 

1. Best Time To Buy Dividend Stocks

2. How RBI Policies Affect Dividend Stocks

3. Can Dividend Stocks Beat Inflation

4. What Is The Dividend Aristocrat List

5. Which Indian Psus Offer The Best Dividends

6. Large Cap Vs Small Cap Dividend Stocks